US5595886A
(en)
*
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US6048729A
(en)
*
|
1987-05-01 |
2000-04-11 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6544771B1
(en)
|
1987-12-11 |
2003-04-08 |
Cell Genesys, Inc. |
Retroviral gene therapy vectors and therapeutic methods based thereon
|
WO1993000103A1
(en)
*
|
1991-06-21 |
1993-01-07 |
The Wistar Institute Of Anatomy And Biology |
Chimeric envelope proteins for viral targeting
|
ATE322286T1
(de)
*
|
1991-10-04 |
2006-04-15 |
Whitehead Biomedical Inst |
Regulierung der systemischen immunantworten mittels zytokinen und antigenen
|
US5637483A
(en)
*
|
1991-10-04 |
1997-06-10 |
Whitehead Institute For Biomedical Research |
Irradiated tumor cell vaccine engineered to express GM-CSF
|
US5904920A
(en)
*
|
1991-10-04 |
1999-05-18 |
Whitehead Institute For Biomedical Research |
Regulation of systemic immune responses utilizing cytokines and antigens
|
US6692737B1
(en)
|
1991-11-05 |
2004-02-17 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6063630A
(en)
|
1991-11-05 |
2000-05-16 |
Transkaryotic Therapies, Inc. |
Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
|
US6054288A
(en)
*
|
1991-11-05 |
2000-04-25 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
PT101031B
(pt)
|
1991-11-05 |
2002-07-31 |
Transkaryotic Therapies Inc |
Processo para o fornecimento de proteinas por terapia genetica
|
EP0646010A4
(de)
*
|
1992-06-19 |
1997-04-23 |
Gen Hospital Corp |
Verwendung von müllerscher inhibierender substanz zur behandlung von tumoren und zur modulation der expression von klasse 1-haupthistokompatibilitätsantigen.
|
US5911983A
(en)
*
|
1992-06-26 |
1999-06-15 |
University Of Pittsburgh |
Gene therapy for Gaucher disease using retroviral vectors
|
US6670178B1
(en)
|
1992-07-10 |
2003-12-30 |
Transkaryotic Therapies, Inc. |
In Vivo production and delivery of insulinotropin for gene therapy
|
US6531124B1
(en)
|
1992-07-10 |
2003-03-11 |
Transkaryotic Therapies, Inc. |
In vivo production and delivery of insulinotropin for gene therapy
|
GB9222931D0
(en)
*
|
1992-11-02 |
1992-12-16 |
Sandoz Ltd |
Organic compounds
|
US5830461A
(en)
*
|
1992-11-25 |
1998-11-03 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Methods for promoting wound healing and treating transplant-associated vasculopathy
|
US5658565A
(en)
*
|
1994-06-24 |
1997-08-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Inducible nitric oxide synthase gene for treatment of disease
|
JPH08511507A
(ja)
*
|
1993-03-08 |
1996-12-03 |
ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション |
哺乳動物宿主の結合組織を処置するための遺伝子導入
|
FR2704236B1
(fr)
*
|
1993-04-21 |
1995-06-23 |
Pasteur Institut |
Vecteur rétroviral pour la préparation de cellules recombinantes susceptibles d'être implantées in vivo dans un but thérapeutique.
|
DK0702723T3
(da)
|
1993-04-21 |
2003-01-13 |
Pasteur Institut |
Biokompatibelt implantat til ekspression og udskillelse af terapeutisk forbindelse in vivo
|
US5591625A
(en)
*
|
1993-11-24 |
1997-01-07 |
Case Western Reserve University |
Transduced mesenchymal stem cells
|
AU1513495A
(en)
*
|
1993-12-14 |
1995-07-03 |
University Of Pittsburgh |
Systemic gene treatment of connective tissue diseases
|
DE4411402A1
(de)
*
|
1994-03-31 |
1995-10-05 |
Juergen Schrader |
DNA-Expressionsvektoren zur Verwendung in der gentherapeutischen Behandlung von Gefäßerkrankungen
|
DK0758394T3
(da)
|
1994-05-02 |
2003-03-03 |
Bernd Groner |
Bifunktionelt protein, fremstilling og anvendelse
|
JP4303315B2
(ja)
*
|
1994-05-09 |
2009-07-29 |
オックスフォード バイオメディカ(ユーケー)リミテッド |
非交差性レトロウイルスベクター
|
US6013517A
(en)
*
|
1994-05-09 |
2000-01-11 |
Chiron Corporation |
Crossless retroviral vectors
|
US6150137A
(en)
|
1994-05-27 |
2000-11-21 |
Ariad Pharmaceuticals, Inc. |
Immunosuppressant target proteins
|
WO1996006933A1
(en)
*
|
1994-08-26 |
1996-03-07 |
Sandoz Ltd. |
Gene therapy for transplantation and inflammatory or thrombotic conditions
|
FR2726005B1
(fr)
*
|
1994-10-10 |
1997-01-03 |
Adim |
Lignees immortalisees de cellules endotheliales cerebrales et leurs applications au traitement de differents troubles ou maladies primaires et secondaires neurologiques ou psychiatriques
|
US6818439B1
(en)
|
1994-12-30 |
2004-11-16 |
Chiron Corporation |
Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
|
AU6410596A
(en)
*
|
1995-07-31 |
1997-02-26 |
Centre De Recherche De L'hopital Sainte-Justine |
Cytidine deaminase cdna as a positive selectable marker for ene transfer, gene therapy and protein synthesis
|
FR2737731B1
(fr)
|
1995-08-07 |
1997-10-10 |
Pasteur Institut |
Sequence de retroelements naturels ou synthetiques ayant pour fonction de permettre l'insertion de sequences nucleotidiques dans une cellule eucaryote
|
AU1073797A
(en)
*
|
1995-11-14 |
1997-06-05 |
Somatix Therapy Corporation |
Joint expression of gtp cyclohydrolase and tyrosine hydroxylase
|
US5837464A
(en)
*
|
1996-01-29 |
1998-11-17 |
Virologic, Inc. |
Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
|
US6242187B1
(en)
|
1996-01-29 |
2001-06-05 |
Virologic, Inc. |
Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
|
US6689757B1
(en)
|
1996-02-12 |
2004-02-10 |
M.L. Laboratories Plc |
Methods for vaccination and vaccines therefor
|
CA2245503A1
(en)
*
|
1996-02-14 |
1997-08-21 |
Novartis Ag |
Gene therapy of entothelial cells with anti-apoptotic proteins for transplantation and inflammatory conditions
|
US5965126A
(en)
*
|
1996-03-25 |
1999-10-12 |
The Penn State Research Foundation |
use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
|
US6723531B2
(en)
|
1996-04-05 |
2004-04-20 |
The Salk Institute For Biological Studies |
Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
AUPN970196A0
(en)
*
|
1996-05-06 |
1996-05-30 |
Unisearch Limited |
A long-term and high expression, single gene retroviral vector with applications to progenitor and mature haematopoietic cells
|
US6027721A
(en)
*
|
1996-05-20 |
2000-02-22 |
Cytotherapeutics, Inc. |
Device and method for encapsulated gene therapy
|
EP0915967A1
(de)
*
|
1996-05-28 |
1999-05-19 |
The Board Of Regents Of The University Of Michigan |
Entwicklung von oralem gewebe
|
US6001816A
(en)
*
|
1996-06-20 |
1999-12-14 |
Merck & Co., Inc. |
Gene therapy for leptin deficiency
|
CA2258755A1
(en)
*
|
1996-06-20 |
1997-12-24 |
Merck & Co., Inc. |
Gene therapy for obesity
|
KR100246096B1
(ko)
*
|
1996-09-21 |
2000-03-15 |
이선경 |
유전자 요법을 위한 개선된 레트로바이러스 벡터
|
US8075880B2
(en)
|
1999-01-11 |
2011-12-13 |
Steward St. Elizabeth's Medical Center Of Boston, Inc. |
Compositions and methods for regulating angiogenesis
|
US5980887A
(en)
|
1996-11-08 |
1999-11-09 |
St. Elizabeth's Medical Center Of Boston |
Methods for enhancing angiogenesis with endothelial progenitor cells
|
US5833651A
(en)
|
1996-11-08 |
1998-11-10 |
Medtronic, Inc. |
Therapeutic intraluminal stents
|
WO1998042854A1
(en)
*
|
1997-03-27 |
1998-10-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Functional genomic screen for rna regulatory sequences and interacting molecules
|
US6300488B1
(en)
|
1997-07-10 |
2001-10-09 |
The Salk Institute For Biological Studies |
Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
|
EP1027076A2
(de)
|
1997-10-29 |
2000-08-16 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Verwendung von vektoren wie adenoviren und/oder adeno-assoziierten viren und/oder retroviren und/oder herpes-simplex-viren und/oder liposomen und/oder plasmiden als vehikel für genetische information zur befähigung von säugetierzellen mittel, zur behandlung von knochenpathologien zu produzieren
|
ATE258444T1
(de)
|
1998-03-13 |
2004-02-15 |
Univ British Columbia |
Therapeutische chemokine rezeptor antagonisten
|
CA2245224A1
(en)
|
1998-08-14 |
2000-02-14 |
Jiang-Hong Giong |
Chemokine receptor antagonists and chemotherapeutics
|
CA2305787A1
(en)
|
2000-05-09 |
2001-11-09 |
The University Of British Columbia |
Cxcr4 antagonist treatment of hematopoietic cells
|
US6743631B1
(en)
|
1998-03-17 |
2004-06-01 |
North Shore University Hospital Research Corporation |
Use of human serum resistant vector particles and cell lines for human gene therapy
|
US6841538B1
(en)
|
1998-04-22 |
2005-01-11 |
Inex Pharmaceuticals Corporation |
Combination therapy using nucleic acids and radio therapy
|
US6841537B1
(en)
|
1998-04-22 |
2005-01-11 |
Protiva Biotherapeutics Inc. |
Combination therapy using nucleic acids and conventional drugs
|
DE19822115B4
(de)
*
|
1998-05-08 |
2004-04-08 |
Heinrich-Pette-Institut |
Retrovirale Gentransfervektoren
|
US6333318B1
(en)
|
1998-05-14 |
2001-12-25 |
The Salk Institute For Biological Studies |
Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
WO1999059622A1
(en)
*
|
1998-05-20 |
1999-11-25 |
Genentech, Inc. |
Treatment for hemophilia
|
CA2333481A1
(en)
*
|
1998-05-26 |
2000-01-06 |
Lung-Ji Chang |
Lentiviral vectors, comprising modified major donor splice sites and major packaging signals
|
US6319905B1
(en)
|
1998-12-29 |
2001-11-20 |
Cell Genesys, Inc. |
Method of controlling L-Dopa production and of treating dopamine deficiency
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
JP2002538167A
(ja)
|
1999-03-03 |
2002-11-12 |
バイオジェン インコーポレイテッド |
脂質の代謝および貯蔵を調節する方法
|
WO2000053743A1
(en)
|
1999-03-12 |
2000-09-14 |
Gpc Biotech, Inc. |
Methods and reagents for identifying synthetic genetic elements
|
US7396905B1
(en)
|
1999-05-21 |
2008-07-08 |
Mckeon Frank |
Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
|
US7504253B2
(en)
|
1999-06-11 |
2009-03-17 |
The Burnham Institute For Medical Research |
Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
|
US7057015B1
(en)
|
1999-10-20 |
2006-06-06 |
The Salk Institute For Biological Studies |
Hormone receptor functional dimers and methods of their use
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
US8168178B2
(en)
|
1999-11-30 |
2012-05-01 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
US6951839B1
(en)
|
1999-11-30 |
2005-10-04 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
GB9930616D0
(en)
|
1999-12-24 |
2000-02-16 |
Mathilda & Terence Kennedy Ins |
Activation and inhibition of the immune system
|
CA2396062C
(en)
|
1999-12-30 |
2009-11-17 |
President And Fellows Of Harvard College |
Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or t cell subset activity by modulation of xbp-1 activity
|
WO2001052639A1
(en)
|
2000-01-21 |
2001-07-26 |
Beth Israel Deaconess Medical Center |
Use of pro-apoptotic factors in treatment of atherosclerosis
|
US7378098B2
(en)
|
2000-04-12 |
2008-05-27 |
The University Of British Columbia |
CXC chemokine receptor 4 agonist peptides
|
US20050059584A1
(en)
|
2002-08-16 |
2005-03-17 |
Ahmed Merzouk |
Novel chemokine mimetics synthesis and their use
|
US7368425B2
(en)
|
2006-03-24 |
2008-05-06 |
Chemokine Therapeutics Corp. |
Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
|
EP1353702A2
(de)
|
2000-05-22 |
2003-10-22 |
The Johns Hopkins University |
Genmanipulation der gefässtransplantat zur resistenz gegen erkrankungen
|
CN100421727C
(zh)
|
2000-12-22 |
2008-10-01 |
玛蒂尔达和特伦斯·肯尼迪风湿病学信托学会 |
方法
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
EP1900815B1
(de)
|
2001-07-12 |
2016-09-07 |
University of Massachusetts |
In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
|
EP2360251B1
(de)
|
2001-07-12 |
2016-09-28 |
University of Massachusetts |
In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
IL152904A0
(en)
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
CA2421269A1
(en)
|
2002-08-09 |
2004-02-09 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
US7470538B2
(en)
|
2002-12-05 |
2008-12-30 |
Case Western Reserve University |
Cell-based therapies for ischemia
|
CA2513251C
(en)
|
2003-01-14 |
2013-03-19 |
Dana-Farber Cancer Institute |
Cancer therapy sensitizer
|
DK1624936T3
(da)
|
2003-05-16 |
2010-03-15 |
Univ Laval |
CNS-chloridmodulering og anvendelser deraf
|
PL1633767T3
(pl)
|
2003-06-02 |
2019-07-31 |
University Of Massachusetts |
Sposoby i kompozycje do kontrolowania wydajności wyciszania rna
|
ES2864206T3
(es)
|
2003-06-02 |
2021-10-13 |
Univ Massachusetts |
Métodos y composiciones para mejorar la eficacia y la especificidad del ARNi
|
US7576052B2
(en)
|
2003-10-17 |
2009-08-18 |
Joslin Diabetes Center, Inc. |
Methods and compositions for modulating adipocyte function
|
AU2005222902B2
(en)
|
2004-03-12 |
2010-06-10 |
Alnylam Pharmaceuticals, Inc. |
iRNA agents targeting VEGF
|
EP1740219B1
(de)
*
|
2004-04-30 |
2015-03-04 |
OrbusNeich Medical, Inc. |
Medizinprodukt mit beschichtung zur erfassung von genetisch veränderten zellen und anwendungsverfahren dafür
|
ATE551432T1
(de)
|
2004-06-21 |
2012-04-15 |
Univ Leland Stanford Junior |
Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege
|
CA2576193A1
(en)
|
2004-08-03 |
2006-02-16 |
Biogen Idec Ma Inc. |
Taj in neuronal function
|
DK2529619T3
(en)
|
2005-02-17 |
2016-01-11 |
Biogen Ma Inc |
Treatment of neurological disorders
|
KR101272896B1
(ko)
|
2005-08-16 |
2013-06-25 |
다카라 바이오 가부시키가이샤 |
면역 결핍 바이러스 감염의 치료 또는 예방을 위한 핵산
|
ATE552334T1
(de)
|
2005-09-13 |
2012-04-15 |
Takara Bio Inc |
Serumfreies medium zur herstellung von retroviralen vektoren
|
EP1942948A4
(de)
|
2005-11-04 |
2010-03-03 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur hemmung der expression des nav1.8-genes
|
EP1945270B1
(de)
|
2005-11-09 |
2011-05-25 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von faktor v leiden mutationsgen
|
AU2006315562C1
(en)
|
2005-11-12 |
2013-10-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for treating depression using NCAM peptide mimetics
|
CN101360826B
(zh)
|
2005-11-18 |
2014-04-30 |
格兰马克药品股份有限公司 |
抗α2整联蛋白抗体及它们的用途
|
CA2524619A1
(en)
|
2005-11-22 |
2007-05-22 |
Ottawa Health Research Institute |
Novel stem cells, nucleotide sequences and proteins therefrom
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
KR101547579B1
(ko)
|
2006-03-31 |
2015-08-27 |
알닐람 파마슈티칼스 인코포레이티드 |
Eg5 유전자의 발현을 억제하는 이본쇄 리보핵산
|
US7691824B2
(en)
|
2006-04-28 |
2010-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the JC virus
|
NZ587616A
(en)
|
2006-05-11 |
2012-03-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of the pcsk9 gene
|
ATE528008T1
(de)
|
2006-05-19 |
2011-10-15 |
Alnylam Pharmaceuticals Inc |
Rnai-modulation von aha und ihre therapeutische verwendung
|
EP2192200B1
(de)
|
2006-05-22 |
2012-10-24 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der IKK-B-Gen-Expression
|
DK2034830T3
(da)
|
2006-05-25 |
2014-10-27 |
Biogen Idec Inc |
Anti-vla-1-antistof til behandling af slagtilfælde
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
EP2111553B1
(de)
|
2007-01-24 |
2018-09-19 |
Carnegie Mellon University |
Optische biosensoren
|
AU2008213999B2
(en)
|
2007-02-06 |
2014-04-17 |
Tai June Yoo |
Treatment and prevention of neurodegenerative diseases using gene therapy
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
US20100137415A1
(en)
|
2007-04-20 |
2010-06-03 |
Takara Bio Inc. |
Vector for gene therapy
|
WO2009004085A2
(en)
|
2007-07-05 |
2009-01-08 |
Novartis Ag |
Dsrna for treating viral infection
|
CA2707042A1
(en)
|
2007-12-10 |
2009-06-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor vii gene
|
US8324182B2
(en)
|
2008-02-15 |
2012-12-04 |
Tufts University |
Humanized model of membrane attack complex (MAC) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
|
US8877896B2
(en)
|
2008-02-15 |
2014-11-04 |
Tufts University |
Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
|
KR101397407B1
(ko)
|
2008-03-05 |
2014-06-19 |
알닐람 파마슈티칼스 인코포레이티드 |
Eg5 및 VEGF 유전자의 발현을 억제하기 위한 조성물 및 방법
|
WO2009137613A2
(en)
|
2008-05-06 |
2009-11-12 |
Joslin Diabetes Center, Inc. |
Methods and compositions for inducing brown adipogenesis
|
EP3208337A1
(de)
|
2008-09-02 |
2017-08-23 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
|
US8546554B2
(en)
|
2008-09-25 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
|
AU2009307677C1
(en)
|
2008-10-20 |
2022-09-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
ES2940466T3
(es)
|
2008-11-10 |
2023-05-08 |
Alexion Pharma Inc |
Métodos y composiciones para tratar trastornos asociados al complemento
|
EP2373382B1
(de)
|
2008-12-10 |
2017-02-15 |
Alnylam Pharmaceuticals, Inc. |
Auf gnaq zielende dsrna-zusammensetzungen und verfahren zur unterdrückung der expression
|
JP2009148273A
(ja)
*
|
2009-01-21 |
2009-07-09 |
Ichikazu Nakao |
内皮細胞を分化増殖させる方法
|
MX2011008936A
(es)
|
2009-02-24 |
2011-09-21 |
Alexion Pharma Inc |
Anticuerpos que contienen peptidos terapeuticos mimeticos de tpo/epo.
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
NZ594995A
(en)
|
2009-03-12 |
2013-06-28 |
Alnylam Pharmaceuticals Inc |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
|
US9487756B2
(en)
|
2009-03-20 |
2016-11-08 |
Mesoblast, Inc. |
Production of reprogrammed pluripotent cells
|
WO2011005496A2
(en)
|
2009-06-22 |
2011-01-13 |
Massachusetts Eye & Ear Infirmary |
Islet1 (isl1) and hearing loss
|
JPWO2011024791A1
(ja)
|
2009-08-25 |
2013-01-31 |
タカラバイオ株式会社 |
レチノイン酸存在下でのt細胞集団の製造方法
|
EP2491145B1
(de)
|
2009-10-21 |
2016-03-09 |
Agios Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen für zellproliferationsbedingte erkrankungen
|
US9745589B2
(en)
|
2010-01-14 |
2017-08-29 |
Cornell University |
Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
|
EP3329924B1
(de)
|
2010-03-29 |
2021-05-05 |
Alnylam Pharmaceuticals, Inc. |
Dsrna-therapie für durch transthyretin (ttr) vermittelte augenamyloidose
|
SG185383A1
(en)
|
2010-04-30 |
2012-12-28 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
CA2843684A1
(en)
|
2010-08-13 |
2012-02-16 |
Tufts University |
Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
|
WO2012046727A1
(ja)
|
2010-10-05 |
2012-04-12 |
タカラバイオ株式会社 |
ウイルスベクターの製造方法
|
WO2012051301A1
(en)
|
2010-10-12 |
2012-04-19 |
President And Fellows Of Harvard College |
Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
|
US8815942B2
(en)
|
2010-10-20 |
2014-08-26 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
|
WO2012092299A1
(en)
|
2010-12-27 |
2012-07-05 |
Brown University |
Therapeutic and diagnostic methods involving biglycan and utrophin
|
WO2012109238A2
(en)
|
2011-02-07 |
2012-08-16 |
President And Fellows Of Harvard College |
Methods for increasing immune responses using agents that directly bind to and activate ire-1
|
RU2631805C2
(ru)
|
2011-06-21 |
2017-09-26 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
|
EP2723351B1
(de)
|
2011-06-21 |
2018-02-14 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
|
CN103998057A
(zh)
|
2011-09-15 |
2014-08-20 |
美国加州大学洛杉矶海滨分校医学中心的洛杉矶生物医学研究所 |
利用CotH的毛霉菌病的免疫疗法和诊断
|
CN104204192A
(zh)
|
2012-02-13 |
2014-12-10 |
加米达细胞有限公司 |
间充质干细胞调理的基质及其产生和使用方法
|
US9399780B2
(en)
|
2012-03-22 |
2016-07-26 |
Takara Bio Inc. |
Method for producing viral vector
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
US20140120116A1
(en)
|
2012-10-26 |
2014-05-01 |
The Chinese University Of Hong Kong |
Treatment of cancer using smad3 inhibitor
|
EP2946013A1
(de)
|
2013-01-16 |
2015-11-25 |
Iowa State University Research Foundation, Inc. |
Tiefes intronisches ziel zur spleisskorrektur des spinalen muskelatrophiegens
|
EP2851086A1
(de)
|
2013-09-20 |
2015-03-25 |
Sanofi |
Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
|
EP2769732A1
(de)
|
2013-02-22 |
2014-08-27 |
Sanofi |
Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
|
WO2014128257A1
(en)
|
2013-02-22 |
2014-08-28 |
Sanofi |
Serpins: methods of therapeutic beta-cell regeneration and function
|
BR112015023108A8
(pt)
|
2013-03-13 |
2018-01-23 |
Geneweave Biosciences Inc |
sistema de acondicionamento de célula bacteriana, método para acondicionamento de uma molécula de ácido nucléico repórter, composição, método para detectar uma presença ou uma ausência de uma célula bacteriana em uma amostra, vetor, método para detectar um transcrito alvo em uma célula, método para detectar a presença de uma célula bacteriana em uma amostra e kit.
|
EP3003022B1
(de)
|
2013-06-04 |
2017-11-22 |
Virginia Commonwealth University |
Verwendung eines trunkierten ccn1-promotors für krebsdiagnostik, therapeutika und theranostika
|
EP3004872B1
(de)
|
2013-06-04 |
2017-10-18 |
Virginia Commonwealth University |
Mda-9/syntenin-promotor zur abbildung und behandlung metastatischer krebszellen
|
US10166300B2
(en)
|
2013-06-04 |
2019-01-01 |
Virginia Commonwealth University |
Tripartite cancer theranostic nucleic acid constructs
|
WO2014197535A1
(en)
|
2013-06-04 |
2014-12-11 |
Virginia Commonwealth University |
Recombinant cancer therapeutic cytokine
|
WO2014197599A1
(en)
|
2013-06-04 |
2014-12-11 |
The Johns Hopkins University |
Peg-prom mediated surface expression of avidin/streptavidin
|
DK3049521T3
(en)
|
2013-09-25 |
2019-04-23 |
Univ Cornell |
Compounds for inducing antitumor immunity and methods thereof
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
EP3191139B1
(de)
|
2014-07-24 |
2020-10-07 |
Massachusetts Eye & Ear Infirmary |
Rpgr-gentherapie für retinitis pigmentosa
|
EP3892291A1
(de)
|
2014-08-28 |
2021-10-13 |
Tufts University |
Zusammensetzungen, verfahren und kits zur behandlung komplementär hervorgerufener erkrankungen
|
US10632151B2
(en)
|
2015-01-22 |
2020-04-28 |
University Of Massachusetts |
Cancer immunotherapy
|
WO2016123454A1
(en)
|
2015-01-29 |
2016-08-04 |
Board Of Trustees Of Miching State University |
Cryptic polypeptides and uses thereof
|
RS60668B1
(sr)
|
2015-03-06 |
2020-09-30 |
Massachusetts Eye & Ear Infirmary |
Terapije augmentacije gena za naslednu degeneraciju retine uzrokovanu mutacijama u genu prpf31
|
EP3735982A1
(de)
|
2015-03-10 |
2020-11-11 |
The University of Massachusetts |
Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
|
US20180104331A1
(en)
|
2015-05-11 |
2018-04-19 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
EP3294332A4
(de)
|
2015-05-14 |
2018-12-26 |
Joslin Diabetes Center, Inc. |
Retinolbindendes protein 3 (rbp3) als schutzfaktor bei nicht diabetischer netzhautdegeneration
|
US9920100B2
(en)
|
2015-06-05 |
2018-03-20 |
The Chinese University Of Hong Kong |
Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy
|
WO2017066712A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
WO2017066796A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
EP3377086B1
(de)
|
2015-11-19 |
2024-05-01 |
The Brigham and Women's Hospital, Inc. |
Lymphozytenantigen cd5-like(cd5l)-interleukin 12b (p40)-heterodimere in der immunität
|
WO2017117218A1
(en)
|
2015-12-30 |
2017-07-06 |
Momenta Pharmaceuticals, Inc. |
Methods related to biologics
|
EP3299460A1
(de)
|
2016-09-26 |
2018-03-28 |
Johann Wolfgang Goethe-Universität Frankfurt am Main |
Neuartige verbindungen und verfahren zur modulation der ubiquitinierung
|
EP3532638A4
(de)
|
2016-10-31 |
2020-07-29 |
University of Massachusetts |
Targeting von microrna-101-3p in der krebstherapie
|
US11795201B2
(en)
|
2017-04-14 |
2023-10-24 |
University Of Massachusetts |
Brown fat-selective adipokines
|
WO2018194438A1
(ko)
|
2017-04-21 |
2018-10-25 |
(주)지뉴인텍 |
비복제 아데노 바이러스 생산 세포주 및 이의 제조방법
|
WO2019005897A1
(en)
|
2017-06-28 |
2019-01-03 |
Regeneron Pharmaceuticals, Inc. |
HUMAN ANTI-PAPILLOMAVIRUS ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
DK3658184T3
(da)
|
2017-07-27 |
2023-11-27 |
Alexion Pharma Inc |
Højkoncentrerede anti-c5-antistofformuleringer
|
US11008602B2
(en)
|
2017-12-20 |
2021-05-18 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
JP7430394B2
(ja)
|
2018-02-12 |
2024-02-13 |
トラスティーズ オブ タフツ カレッジ |
インフラマソームの活性化を阻害するためのcd59
|
CA3102182A1
(en)
|
2018-06-01 |
2019-12-05 |
Sanofi |
Combination therapy for treating hepatitis b virus infection
|
ES2973946T3
(es)
|
2018-07-19 |
2024-06-25 |
Regeneron Pharma |
Receptores de antígenos quiméricos con especificidad por el BCMA y usos de los mismos
|
CA3117539A1
(en)
|
2018-10-23 |
2020-04-30 |
Regeneron Pharmaceuticals, Inc. |
Ny-eso-1 t cell receptors and methods of use thereof
|
WO2020097261A1
(en)
|
2018-11-06 |
2020-05-14 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
New compositions and methods for treating beta-globinopathies
|
WO2020120649A1
(en)
|
2018-12-13 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
|
JP2022515451A
(ja)
|
2018-12-27 |
2022-02-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
アシネトバクター・バウマンニの検出のための、非複製的形質導入粒子及び形質導入粒子に基づくレポーター系
|
US11572595B2
(en)
|
2018-12-31 |
2023-02-07 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
|
IT201900007060A1
(it)
|
2019-05-21 |
2020-11-21 |
St Superiore Di Sanita |
Cellule tumorali ingegnerizzate e loro usi
|
IT201900012540A1
(it)
|
2019-07-22 |
2021-01-22 |
Humanitas Mirasole Spa |
Inibitori di CHI3L1 e loro usi
|
US20220281994A1
(en)
|
2019-07-24 |
2022-09-08 |
Regeneron Pharmaceuticals, Inc. |
Chimeric Antigen Receptors with MAGE-A4 Specificity and Uses Thereof
|
AU2020328507A1
(en)
|
2019-08-12 |
2022-03-17 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
WO2021067526A1
(en)
|
2019-10-02 |
2021-04-08 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
WO2021074695A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
|
IL293450A
(en)
|
2019-12-03 |
2022-07-01 |
Evotec Int Gmbh |
Interferon-related antigen-binding proteins and uses thereof
|
US20230028476A1
(en)
|
2019-12-03 |
2023-01-26 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use in treating hepatitis b infection
|
WO2021136752A1
(en)
|
2019-12-31 |
2021-07-08 |
F. Hoffmann-La Roche Ag |
Quantitative pcr screening of inducible prophage from bacterial isolates
|
EP4084819A1
(de)
|
2020-01-03 |
2022-11-09 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Lokal verabreichtes tnap zum fördern der periodontalen gesundheit
|
IL294988A
(en)
|
2020-01-24 |
2022-09-01 |
Regeneron Pharma |
Antigen preferentially expressed in melanoma t-cell receptors (prame) and methods of using them
|
WO2021217024A1
(en)
|
2020-04-24 |
2021-10-28 |
Millennium Pharmaceuticals, Inc. |
Anti-cd19 antibodies and uses thereof
|
BR112022021871A2
(pt)
|
2020-05-05 |
2023-01-31 |
Regeneron Pharma |
Polipeptídeo car, composição, ácido nucleico, célula imune, método para tratar um tumor, e, banco de células
|
KR20230069961A
(ko)
|
2020-09-14 |
2023-05-19 |
보르 바이오파마 인크. |
Cd33에 대한 단일 도메인 항체
|
CA3205574A1
(en)
|
2020-12-18 |
2022-06-23 |
Momenta Pharmaceuticals, Inc. |
Antibodies against integrin alpha 11 beta 1
|
EP4320149A1
(de)
|
2021-04-09 |
2024-02-14 |
Takeda Pharmaceutical Company Limited |
Gegen komplementfaktor d gerichtete antikörper und verwendungen davon
|
WO2022232035A1
(en)
|
2021-04-26 |
2022-11-03 |
Millennium Pharmaceuticals, Inc. |
Anti-adgre2 antibodies and uses thereof
|
CA3216770A1
(en)
|
2021-04-26 |
2022-11-03 |
Tomoki Yoshihara |
Anti-clec12a antibodies and uses thereof
|
AU2022271212A1
(en)
|
2021-05-04 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
EP4337770A1
(de)
|
2021-05-13 |
2024-03-20 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Zusammensetzungen und verfahren zur behandlung von sichelzellkrankheiten
|
JP2024521958A
(ja)
|
2021-06-09 |
2024-06-04 |
エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
コロナウイルス感染の処置又は予防のための使用のためのインターフェロン会合抗原結合性タンパク質
|
WO2023057946A1
(en)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Serum half-life extended pd-l1 binding polypeptides
|
TW202334196A
(zh)
|
2021-10-07 |
2023-09-01 |
英商阿法克塔生命科學有限公司 |
Pd-l1結合多肽
|
WO2023064255A2
(en)
|
2021-10-15 |
2023-04-20 |
The Regents Of The University Of California |
Diagnosis and treatment of anti-pf4 induced thrombocytopenia
|
IL311837A
(en)
|
2021-10-20 |
2024-05-01 |
Takeda Pharmaceuticals Co |
BCMA designated preparations and methods for their use
|
WO2023081167A2
(en)
|
2021-11-02 |
2023-05-11 |
The Regents Of The University Of California |
P-selectin mutants and modulation of integrin-mediated signaling
|
WO2023089564A1
(en)
|
2021-11-19 |
2023-05-25 |
Janssen Biotech, Inc. |
Method of treating geographic atrophy with a gene therapy vector expressing soluble cd59
|
WO2023146807A1
(en)
|
2022-01-25 |
2023-08-03 |
The Regents Of The University Of California |
Vegf mutants and modulation of integrin-mediated signaling
|
WO2023201238A1
(en)
|
2022-04-11 |
2023-10-19 |
Vor Biopharma Inc. |
Binding agents and methods of use thereof
|
WO2023200897A1
(en)
|
2022-04-13 |
2023-10-19 |
The Regents Of The University Of California |
Use of viral il-6 in cancer therapy
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|
WO2024126293A1
(en)
|
2022-12-13 |
2024-06-20 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
|
WO2024126294A1
(en)
|
2022-12-13 |
2024-06-20 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
|
WO2024126289A1
(en)
|
2022-12-13 |
2024-06-20 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
|